Background: Chronic obstructive pulmonary disease (COPD) affects millions of people and has limited treatment options. Surgical treatments for severe COPD with emphysema are effective for highly selected patients. A minimally invasive method for treating emphysema could decrease morbidity and increase acceptance by patients. Objective: To study the safety and effectiveness of the IBV® Valve for the treatment of severe emphysema. Methods: A multicenter study treated 91 patients with severe obstruction, hyperinflation and upper lobe (UL)-predominant emphysema with 609 bronchial valves placed bilaterally into ULs. Results: Valves were placed in desired airways with 99.7% technical success and no migration or erosion. There were no procedure-related deaths and 30-day morbidity and mortality were 5.5 and 1.1%, respectively. Pneumothorax was the most frequent serious device-related complication and primarily occurred when all segments of a lobe, especially the left UL, were occluded. Highly significant health-related quality of life (HRQL) improvement (–8.2 ± 16.2, mean ± SD change at 6 months) was observed. HRQL improvement was associated with a decreased volume (mean –294 ± 427 ml, p = 0.007) in the treated lobes without visible atelectasis. FEV1, exercise tests, and total lung volume were not changed but there was a proportional shift, a redirection of inspired volume to the untreated lobes. Combined with perfusion scan changes, this suggests that there is improved ventilation and perfusion matching in non-UL lung parenchyma. Conclusion: Bronchial valve treatment of emphysema has multiple mechanisms of action and acceptable safety, and significantly improves quality of life for the majority of patients.

Keywords:
Bronchial valve, Bronchoscopic treatment of emphysema, Chronic obstructive pulmonary disease, Emphysema, Endobronchial lung volume reduction, Valve placement
1.
Mannino DM, Buist AS: Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007:370:765–773.
2.
Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbol J: Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799–805.
3.
Celli BR: Update on management of COPD. Chest 2008;133:1451–1462.
4.
Make BJ, Martinez FJ: Assessment of patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:884–890.
5.
National Emphysema Treatment Trial Research Group: A randomized trial comparing lung volume reduction with medical therapy for severe emphysema. N Engl J Med 2003;348:2059–2073.
6.
Naunheim KS, Wood DE, Mohsenifar Z, Sternberg AL, Criner GJ, DeCamp MM, Deschamps CC, Martinez FJ, Sciurba FC, Tonascia J, Fishman AP: Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006;82:431–443.
7.
Naunheim KS, Wood DE, Krasna MJ, DeCamp MM Jr, Ginsburg ME, McKenna RJ, Criner GJ, Hoffman E, Sternberg AL, Deschamps C, for the National Emphysema Treatment Trial Research Group: Predictors of operative mortality and cardiopulmonary morbidity in the National Emphysema Treatment Trial. J Thorac Cardiovasc Surg 2006;131:43–53.
8.
Naunheim K: Lung-volume reduction surgery: a vanishing operation? J Thorac Cardiovasc Surg 2007;133:1412–1413.
9.
Sabanathan S, Richardson J, Pieri-Davis S: Bronchoscopic lung volume reduction. J Cardiovasc Surg (Torino) 2003;44:101–108.
10.
Toma TP, Hopkinson NS, Hillier J, Hansell DM, Morgan C, Goldstraw PG, et al: Bronchoscopic volume reduction with valve implants in patients with severe emphysema. Lancet 2003:361:931–933.
11.
Snell GI, Holsworth L, Borrill ZL, Thomson KR, Kalff V, Smith JA, Williams TJ: The potential for bronchoscopic lung volume reduction using bronchial prostheses: a pilot study. Chest 2003;124:1073–1080.
12.
Ingenito EP, Berger RL, Henderson AC, Reilly JJ, Larry Tsai L, Hoffman A: Bronchoscopic lung volume reduction using tissue engineering principles. Am J Respir Crit Care Med 2003;167:771–778.
13.
Rendina EA, De Giacomo T, Venuta F, Coloni GF, Meyers BF, Patterson GA, Cooper JD: Feasibility and safety of the airway bypass procedure for patients with emphysema. J Thorac Cardiovasc Surg 2003;125:1294–1299.
14.
FDA News: FDA Approves Lung Valve to Control Some Air Leaks after Surgery (cited June 26, 2009). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116970.htm
15.
Wood DE, McKenna RJ Jr, Yusen RD, Sterman DH, Ost DE, Springmeyer SC, et al: A multicenter trial of an intrabronchial valve for treatment of severe emphysema. J Thorac Cardiovasc Surg 2007;133:65–73.
16.
Springmeyer SC, Bolliger CT, Waddell TK, Gonzalez X, Wood DE: Treatment of heterogeneous emphysema using the Spiration IBV valves. Thorac Surg Clin 2009;19:247–253.
17.
Coxson HO, Nasute Fauerbach PV, Storness-Bliss C, Muller NL, Cogswell S, Dillard DH, et al: The computed tomography assessment of lung volume changes after bronchial valve treatment. Eur Respir J 2008;32:1443–1450.
18.
Gelb AF, Gutierrez CA, Weisman IM, Newsom R, Taylor CF, Zamel N: Simplified detection of dynamic hyperinflation. Chest 2004;126:1855–1860.
19.
National Emphysema Treatment Trial Research Group: Rationale and design of the National Emphysema Treatment Trial. A prospective randomized trial of lung volume reduction surgery. Chest 1999;116:1750–1761.
20.
Jones PW: Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002;19:398–404.
21.
Jones PW: Health status measurement in chronic obstructive pulmonary disease. Thorax 2001;56:880–887.
22.
Hopkinson NS, Toma TP, Hansell DM, Goldstraw P, Moxham J, Geddes DM, et al: Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med2005;171:453–460.
23.
Krowka MJ, Enright PL, Rodarte JR, Hyatt RE: Effect of effort on measurement of forced expiratory volume in one second. Am Rev Respir Dis 1987;136:829–833.
24.
Suratt PM, Hooe DM, Owens DA, Anne A: Effect of maximal versus submaximal expiratory effort on spirometric values. Respiration 1981;42:233–236.
25.
Nici L, ZuWallack R, Wouters E, Donner CF: On pulmonary rehabilitation and the flight of the bumblebee: the ATS/ERS Statement on Pulmonary Rehabilitation. Eur Respir J 2006;28:461–462.
26.
O’Donnell DE, Lam M, Webb KA: Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542–549.
27.
Nishimura K, Izumi T, Tsukino M, Oga T: Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002;121:1434–1440.
28.
Reilly J: COPD and declining FEV1 – time to divide and conquer? N Engl J Med 2008;359:1616–1618.
29.
Casanova C, Cote CG, Marin JM, de Torres JP, Aguirre-Jaime A, Mendez R, et al: The six-minute walk test: long-term follow up in patients with COPD. Eur Respir J 2007;29:535–540.
30.
Wise RA, Brown CD: Minimally clinically important differences in the six-minute walk test and the incremental shuttle walking test. COPD 2005;2:125–129.
31.
Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP: Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856–1861.
32.
Schols AM, Slangen J, Volovics L, Wouters EF: Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791–1797.
33.
Chetta A, Pisi G, Aiello M, Tzani P, Olivieri D: The walking capacity assessment in the respiratory patient. Respiration 2009;77:361–367.
34.
Ingle L, Rigby AS, Nabb S, Jones PK, Clark AL, Cleland JG: Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease. Eur J Heart Fail 2006;8:321–325.
35.
Colt HG, Matsuo T: Hospital charges attributable to bronchoscopy-related complications in outpatients. Respiration 2001;68:67–72.
36.
Cooper JD, Trulock EP, Triantafillou AN, Patterson GA, Pohl MD, Deloney PA, Sundaresan RS, Roper CL: Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1995;109:106–116.
37.
Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–789.
38.
Washko GR, Fan VS, Ramsey SD, Mohsenifar Z, Martinez F, Make BJ, Sciurba FC, Criner GJ, Minai O, Decamp MM, et al: The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;177:164–169.
39.
Wan IYP, Toma TP, Geddes DM, et al: Bronchoscopic lung volume reduction for end-stage emphysema. Chest 2006;129:518–526.
40.
Strange C, Herth FJF, Kovitz KL, et al: Design of the endobronchial valve for emphysema palliation trial (VENT): a nonsurgical method of lung volume reduction. BMC Pulm Med 2007;7:10.
41.
Pulmonx: Clinical information: VENT Study. http://www.pulmonx.com/clinical-information/vent-study/index.html.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.